The Spark is a Lantern Pharma newsletter that provides succinct and frequent updates about Lantern, our RADR® AI and ML platform, and our pipeline of drug programs. Subscribe to the newsletter to receive it by email or see the most recent editions below.

Lantern Pharma Newsletter May 2023

The May 2023 edition of The Spark features the latest Lantern updates including:

  • Submitted LP-184’s IND application to the FDA - A Phase 1A Trial Expected to Launch During Q2 2023
  • Established New Collaboration with Bielefeld University to Develop Breakthrough Antibody Drug Conjugates (ADCs) using AI
  • Dosed Initial Patients in the Harmonic™ Clinical Trial - A Phase2 Study for Never Smokers with Lung Cancer
  • RADR® Machine Learning Models Accurately Predict Clinical Trial Patient Responses - Results Presented at ASCO 2023 with Actuate Therapeutics
  • Developed Industry Leading AI Algorithms to Predict AnyCompound’s Ability to Cross the Blood-Brain Barrier - a MajorProblem for Drug Development in Neuro-Oncology.
  • In Case You Missed It: Replays of our Q1 Call and RecentInvestor Conferences are Now Available.